Prime Medicine Seeks FDA Accelerated Approval for First-Ever Prime Editing Therapy After Two Patients Achieve Durable Immune Restoration
Prime Medicine is pursuing accelerated approval for PM359, an autologous prime editing therapy that restored immune function in both patients treated for chronic granulomatous disease, marking the first clinical use of prime editing technology.
Overview
Prime Medicine has announced it is pursuing accelerated approval from the U.S. Food and Drug Administration for PM359, an autologous stem cell therapy that uses prime editing to correct a genetic mutation causing chronic granulomatous disease. If granted, it would become the first treatment based on prime editing — a next-generation gene editing technique that rewrites DNA without severing both strands — to receive regulatory authorization anywhere in the world.
The company disclosed its regulatory strategy alongside its full-year 2025 financial results on March 3, stating that it believes clinical data generated to date “may be sufficient to support an accelerated approval” and that it is working toward final alignment with the FDA before submitting a Biologics License Application, according to Prime Medicine’s business update.
What We Know
PM359 targets p47phox-deficient chronic granulomatous disease, a rare inherited immune disorder that prevents white blood cells from producing the chemicals needed to kill certain bacteria and fungi. Patients with CGD face recurrent life-threatening infections and chronic inflammatory complications throughout their lives.
The therapy works by extracting a patient’s own blood-forming stem cells, using prime editing to correct a specific two-nucleotide deletion (delGT) responsible for the disease, and then reinfusing the repaired cells after myeloid conditioning with busulfan. The corrected cells engraft and begin producing functional neutrophils capable of generating the NADPH oxidase activity that CGD patients lack.
Results from the Phase 1/2 trial, published in the New England Journal of Medicine in December 2025, showed that both patients treated with PM359 achieved rapid neutrophil and platelet engraftment, with NADPH oxidase activity restored within one month and maintained through at least six months and four months of follow-up, respectively, as reported by Prime Medicine.
The first patient, 19-year-old Ty Sperle from Kelowna, British Columbia, had been dependent on daily antibiotics and antifungal medications to manage ordinary infections before treatment. According to Earth.com’s reporting, Sperle’s immune system now functions normally, his blood tests confirm stable immune function months after treatment, and he no longer requires daily medications. The second participant showed similar immune restoration within one month, with improvements in biomarkers for inflammatory bowel disease.
Adverse events in both patients were consistent with the busulfan conditioning regimen rather than the prime editing itself. No therapy-linked safety problems have been reported, according to Earth.com.
Why Prime Editing Matters
Prime editing, developed by Broad Institute biochemist David Liu in 2019, represents a fundamental advance over conventional CRISPR-Cas9 gene editing. While standard CRISPR works by cutting both strands of DNA and relying on the cell’s repair machinery to fix the break — a process that can introduce unintended mutations — prime editing uses a guide RNA and an attached reverse transcriptase enzyme to directly write the correct DNA sequence at the target site without making double-strand breaks.
This precision makes prime editing capable of correcting virtually any small genetic error, including insertions, deletions, and point mutations, with fewer off-target effects. The distinction is clinically significant: a Tel Aviv University study has previously documented that conventional CRISPR therapeutics can cause loss of up to 10 percent of genetic material in treated cells, a risk that prime editing is designed to avoid.
Prime Medicine’s decision to seek approval based on data from just two patients reflects both the severity of CGD and the FDA’s evolving posture toward gene editing therapies for rare diseases. As STAT News reported, the application tests an FDA that has promised to accelerate new gene editing treatments through frameworks such as the plausible mechanism pathway announced in February 2026. This follows earlier reporting by The Machine Herald on how the FDA’s new regulatory framework is reshaping the approval landscape for bespoke genetic therapies.
What We Don’t Know
Prime Medicine has not disclosed a specific timeline for its BLA submission, stating only that it is working toward final regulatory alignment with the FDA. The company has also not announced whether additional patients will be enrolled before filing.
With only two patients and a maximum of six months of follow-up, long-term durability remains unconfirmed. Whether the restored immune function will persist for years — as would be expected from a stem cell-based correction — or require retreatment is an open question that only extended monitoring can answer.
The therapy’s applicability beyond p47phox-deficient CGD is also uncertain. While prime editing is theoretically capable of correcting other CGD-causing mutations and a broad range of genetic diseases, each new target would require separate clinical validation. Prime Medicine has not publicly detailed its pipeline beyond PM359.
Finally, manufacturing scalability and cost remain undefined. The current approach requires extracting, editing, and reinfusing each patient’s own stem cells — a labor-intensive process that has historically limited the accessibility of similar autologous cell therapies such as CAR-T treatments.